Savolitinib for non-small cell lung cancer

Savolitinib is a highly selective MET tyrosine kinase inhibitor. MET is involved in numerous cellular pro-cesses such as proliferation, differentiation and the formation of distant metastases. MET amplification and MET overexpression are quite common in many cancers, but MET exon 14 skipping alteration is most common in non-small cell lung cancer (NSCLC). The role of MET signaling as a bypass pathway in the development of acquired resistance to tyrosine kinase inhibitor (TKI) epidermal growth factor recep-tor (EGFR) therapy in cancer patients with EGFR gene mutation was documented. Potential beneficiaries of savolitinib therapy are patients with NSCLC and initial diagnosis of MET ex 14 skipping mutation. Savolitinib therapy can be effective in NSCLC patients with EGFR-mutant MET with progression during first -line treatment with an EGFR-TKI. Antitumor activ-ity of savolitinib in combination with osimertinib is very promising as first-line therapy of patients with advanced EGFR-mutated NSCLC, initially with MET

Automated summary

Savolitinib is a highly selective MET tyrosine kinase inhibitor that can treat acquired resistance to TKI therapy in cancer patients with EGFR gene mutation. It is especially effective in NSCLC patients with MET exon 14 skipping mutation.